Prideapplication/xmlftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/GlobalTMT_HDACi_BRCAWT.mzMLftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B2_T3_F4.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B3_T2_F6.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B2_T2_F10.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B1_T1_F6.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B3_T3_F1.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B3_T2_F10.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B2_T1_F5.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B2_T2_F9.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B1_T2_F3.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B1_T1_F8.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B1_T3_F7.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B1_T2_F12.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B3_T1_F2.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B2_T3_F6.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B3_T1_F4.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B1_T3_F9.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B2_T1_F12.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B1_T2_F1.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B3_T3_F3.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B3_T2_F12.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B1_T1_F1.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B3_T3_F5.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B1_T3_F10.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B3_T2_F4.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B2_T1_F7.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B2_T2_F7.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B1_T3_F11.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B1_T1_F2.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B2_T2_F4.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B1_T2_F6.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B2_T1_F10.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B3_T3_F7.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B1_T2_F8.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B2_T3_F11.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B2_T1_F9.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B3_T2_F2.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B1_T1_F12.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B2_T3_F9.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B1_T3_F2.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B3_T1_F7.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B2_T2_F2.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B2_T1_F2.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B1_T3_F4.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B3_T3_F10.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B1_T1_F4.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B1_T2_F4.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B3_T1_F11.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B3_T2_F9.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B1_T2_F10.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B3_T3_F12.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B3_T3_F9.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B2_T3_F2.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B2_T1_F4.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B1_T2_F11.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B1_T2_F2.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B1_T3_F6.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B3_T1_F1.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B2_T2_F8.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B2_T2_F11.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B3_T2_F7.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B2_T3_F5.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B1_T1_F7.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B3_T3_F2.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B3_T2_F11.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B2_T3_F12.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B1_T2_F9.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B1_T3_F8.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B3_T1_F3.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B1_T1_F9.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B1_T3_F1.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B2_T2_F6.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B3_T2_F3.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B2_T1_F6.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B3_T1_F5.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B3_T2_F5.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B3_T3_F4.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B1_T1_F10.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B2_T3_F7.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B3_T1_F6.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B2_T1_F8.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B3_T3_F6.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B3_T2_F1.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B2_T3_F8.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B1_T1_F11.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B2_T2_F5.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B3_T1_F10.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B1_T3_F3.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B2_T3_F10.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B1_T1_F3.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B1_T2_F7.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B1_T3_F12.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B2_T1_F11.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B2_T2_F12.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B3_T1_F8.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B3_T3_F8.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B3_T1_F9A.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B2_T1_F1.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B2_T2_F1.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B3_T2_F8.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B2_T3_F3.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B2_T1_F3.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B2_T2_F3.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B2_T3_F1.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B1_T2_F5.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B3_T3_F11.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B1_T3_F5.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B3_T1_F12.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/G_B1_T1_F5.rawftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/GlobalTMT_HDACi_BRCAWT.mzid.gzftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/11/PXD036467/GlobalTMT_HDACi_BRCAWT.pdResultprimary200OKJolene DudaEpithelial Cellcell were washed, harvested and lysed with 9M urea lysis buffer. lysed cells were quantified using a BCA assay, then reduced and alkylated with DTT and IAA, overnight trypsin digested and acidified to stop digest. Peptide desalting was carried out with C18 SepPak cartridges, desalted peptides were dried and then TMT labeled. TMT labeling was checked for >99% labeling efficiency, and remainder of samples were quenched and pooled. C18 stage tip desalting was then carried out and data acquisition was carried out using an Orbitrap FusionPrideStefani ThomasCOMPLETElab medicine and pathology, university of minnesota36193784 Duda JM, Twigg CAI, Thomas SN. Differential histone deacetylase inhibitor-induced perturbations of the global proteome landscape in the setting of high-grade serous ovarian cancer. Proteomics. 2022:e2100372 10.1002/pmic.202100372University of Minnesotastefanit@umn.eduMass SpectrometryShotgun proteomicsMalignant Neoplasm Of OvaryHistone deacetylaseHistone deacetylase inhibitorHigh-grade serous ovarian cancerhttps://www.ebi.ac.uk/pride/archive/projects/PXD036467Data processing was performed using Proteome Discoverer (PD) 2.5.0.400 (Thermo Fisher Scientific) and searched with SEQUEST HT against a Homo sapiens database (SwissProt downloaded May 2021). Dynamic modifications included methionine oxidation. Protein terminus dynamic modifications included acetyl, met-loss, met-loss + acetyl. Static modifications included TMTpro (static and peptide N-terminus), and cysteine carbamidomethylation.. The cleavage enzyme was trypsin with 2 missed cleavages allowed. The fragment mass tolerance was set to 0.6 Da, and the precursor mass tolerance was set to10 ppm.. The results from PD searches were filtered for high protein and peptide FDR confidence (<0.01) . Peptides were also filtered for abundances > 0 across all samples and filtered for 2 peptides per protein. Peptide abundances were log2 transformed and normalized based on the median value of each treatment condition for each sample. The relative abundance was calculated by dividing the grouped abundances/reference of the treatment condition by the grouped abundance/reference of the DMSO/reference no treatment condition. . Peptides with CVs ≥ 30% across replicates within each condition were removed from the overall dataset. Protein quantitation was obtained by median averaging the peptides and their abundances.ProteomicsHomo Sapiens (human)duda0032@umn.eduHuman proteome projectUnited States10.6019/PXD036467High-grade serous ovarian cancer (HGSOC) is the most lethal gynecologic malignancy in women. Its low survival rate is attributed to late detection, relapse, and drug resistance. The lack of effective second-line therapeutics remains a significant challenge. There is an opportunity to incorporate the use of histone deacetylase inhibitors (HDACi) into HGSOC treatment. However, the mechanism and efficacy of HDACi in the context of BRCA-1/2 mutation status is understudied. Therefore, we set out to elucidate how HDACi perturb the proteomic landscape within HGSOC cells. In this work, we used TMT labeling followed by data-dependent acquisition LC-MS/MS to quantitatively determine differences in the global proteomic landscape across HDACi-treated CAOV3, OVCAR3, and COV318 (BRCA-1/2 wildtype) HGSOC cells. We identified significant differences in the HDACi-induced perturbations of global protein regulation across CAOV3, OVCAR3, and COV318 cells. The HDACi Vorinostat and Romidepsin were identified as being the least and most effective in inhibiting HDAC activity across the three cell lines, respectively. Our results provide a justification for the further investigation of the functional mechanisms associated with the differential efficacy of FDA-approved HDACi within the context of HGSOC. This will enhance the efficacy of targeted HGSOC therapeutic treatment modalities that include HDACi.Differential histone deacetylase inhibitor-induced perturbations of the global proteome landscape in the setting of high-grade serous ovarian cancer.Duda Jolene M JM, Twigg Carly A I CAI, Thomas Stefani N SNLine, Therapies, treatment, Therapy, Cell Lines, Treatment, disease management., Therapeutic, Treatments, Cell, LinesMethane, IPP2A2, E 920, Hgfr, cleavage, 5730555F13Rik, protein, 5730420M11Rik, peptide, Polypeptides, L-Isomer Methionine, Methionine, peptido, diseases, HGFR, diseases and disorders, 2-amino-3-mercaptopropanoic acid, Cystein, protein aggregate, WMS, Rheumabene, treatment, C, SET, human disease, Man (Taxonomy), peptides, MUB3_18, TAF-I, cisteina, M, dimethyl sulphoxide, MUB3.18, DmelCG4299, IGAAD, set, Dimethylsulfoxide, DmelCG10574, ppm, sample, disease management, Therapies, Homo sapiens disease, Half Cystine, RG7MT1, GPHYSD2, Racemethionine, Dimethylsulfoxid, SGS, phapii, Therapy, sulfinylbis-, proto-oncogene c-Met, DMSO, dimethyli sulfoxidum, Data Set, dmso, Zinc Cysteinate, PRO, Modern, methylsulfinylmethane, 2-Amino-4-(methylthio)butyric acid, StF-IT-1, 9130215G10Rik, CYS, Cys, results, ACMICD, (CH3)2SO, Methionin, median, Hmet, (2R)-2-amino-3-sulfanylpropanoic acid, Sulfinylbis(methane), and GLY protein 2, Rimso 50, HGF receptor, HGF/SF receptor, parent ion, and GLY protein 1, HLA-DR-associated protein II, DI-2, Rimso50, I-2Dm, L-Cysteine, MASS, CG4299, hCMT1c, c-Met, beta Trypsin, Treatments, human, L-Cystein, I-2PP1, data analysis, disease, TAF-IBETA, precursor ion, Biocatalyst, TAF-Ibeta, Polypeptide, Liquimeth, i2pp2a, Dimethyl, other disease, human being, 2-amino-4-(methylsulfanyl)butanoic acid, Cysteine Hydrochloride, Biocatalysts, L Isomer, L-Zystein, FBN, Gene, dimethylsulfoxyde, Rimso 100, precursor, protein-containing complex, PHAPII, Human, Sulphoxide, HGF, Homo sapiens, ECTOL1, Gene Products, L-Methionine, disease or disorder, F15E12.6, Half-Cystine, RCCP2, Man, Pedameth, S(O)Me2, sulfinylbis(methane), F15E12_6, scatter factor receptor, L Cysteine, E-920, ipp2a2, beta-Trypsin, 2pp2a, Hcys, man, AUTS9, CG10574, OCTD, non-neoplastic, Rimso-50, dimetil sulfoxido, Enzyme, Rimso, Dimethylsulphinyl, data processing, 2-amino-4-(methylthio)butanoic acid, 2PP2A, 10^[-6], CYSTEINE, taf-ibeta, dSET, dSet, FREE CYSTEINE, disorder, peptidos, AI838057, (2R)-2-amino-3-mercaptopropanoic acid, metionina, DL-Methionine, protein complex, Proteins, igaad, disorders, medical condition, L-Isomer, Peptide, group, polypeptide, native protein, I-2PP2A, Dimexide, Dimethylsulphoxide, Protein, Dm I-2, I2PP2A, condition, MFS1, Sulfoxide, Zystein, Data Base, Met, MET, ATCMPG1, WMS2, ATCMPG2, PRSS, ensemble, 2-amino-3-sulfanylpropanoic acid, tyrosine-protein kinase Met, Tripcellim, dimethyl sulfoxide, Sclerosol, L-2-Amino-3-mercaptopropionic acid, Dimethyl Sulphoxide, (R)-2-amino-3-mercaptopropanoic acid, 2-Amino-3-mercaptopropionic acid, sample population, Protein Gene Products, Gene Proteins, Trypure, dSET/TAF-Ibeta, 2610030F17Rik, Therapeutic, Modern Man, SSKS, alpha-amino-gamma-methylmercaptobutyric acid, E920, Peptid, Treatment, Par4, dimethyl sulfur oxide, AA407739, 5730455C01Rik, Peptide., SF receptorHDAC Inhibitor, Histone Deacetylase, Deacetylase Inhibitors, Inhibitors, total expressed protein, malignant ovarian serous tumour, serous ovarian cancer., HDAC Inhibitors, Inhibitor, Deacetylase Inhibitor, Proteomes, Histone, Histone Deacetylase Inhibitor, HDACNup32D, d230, rac-Dithiothreitol, PLIP, determination, threo-1, Cleland's reagent, developmental stage, dTAFII250, Carbamide, Basodexan, 2-(indol-3-yl)ethanoic acid, EfW1, Type 2A-interacting protein, ESA1, Buffer, Productivity, Bca, dmTAF[[II]]230, Karbamid, peptide, Polypeptides, STOP, IAA, Stable tubule-only polypeptide, peptido, reduced, dmTAF1, Taf230, Ly57, dJ69E11.3, Arabidopsis NAC domain containing protein 91, Harnstoff, B1, zk, AGM4, tiny, Carmol, HTATIP, TAF250, (R*, bca, Taf200, l(2)10432, dTAF[[II]]250, TFIID TAF250, peptides, STOP145, cel, cell, E927b, beta-Trypsin, hypoplasia, Taf1p, Indoleacetic acid, labeling, dTAF250, DmelCG4579, ms(2)zk, (indol-3-yl)acetic acid, cPLA2, scientific observation, D1, nup154., peptidos, stage, autolysin activity, necrosis, Lyw-57, l(2)01501, D8Wsu49e, TAF, TIP, PTHB1, thiol methyltransferase activity, BLNK-S, small, 3-butanediol, measuring, 2810411E12Rik, dTAF[[II]]230, TAF[[II]]250, ZC2HC5, BcDNA:LD21772, Map-6, TAF200, l(3)84Ab, BG:DS00004.13, 4-dimercapto-2, HTATIP1, TAFII-250, TAF250/230, tip, buffer, ANAC091, Cell, ur, Dithiothreitol, Peptide, dTAF230, Dithiotreitol, polypeptide, SLP65, Putative MAPK-activating protein PM10, carbamide, Ly-57, TPSG1, TAFII250, (Indol-3-yl)acetate, S-adenosyl-L-methionine:thiol S-methyltransferase activity, carbonyldiamide, C18, p230, chemical analysis, DL-threo-1, TAF[[II]]250/230, TFIID, bacteriocin activity, Mtap6, 145-kDa STOP, IES, TIP60, DTL, MAP-6, Taf[[II]]250, SLP-65, DTT, nup32D, TAF[[II]]230, holin, PRSS, BASH, underdeveloped, uree, LY57, 3-Indolylessigsaeure, Tripcellim, CG4579, pooled, TAF[II]250, LNKN-1, CDA08, CG17603, TAF[[II]], beta Trypsin, R*)-1, Trypure, H2NC(O)NH2, DmelCG17603, lysin activity, heteroauxin, Taf250, SR3-5, PRSS31, bacteriolytic toxin activity, TCV-interacting protein, Peptid, assay, Polypeptide, tlp, 4-Dimercapto-2, TMT, TIP41, 1728, TAF230, TAF1liquid chromatography tandem mass spectroscopy, 18F-Suberoylanilide Hydroxamic Acid, IPP2A2, Activity, HDAC Inhibitor, FR 901228, protein, sci, Tumor, HDRP, Social Controls, DmelCG7471, 18F Suberoylanilide Hydroxamic Acid, Mutations, 5730420M11Rik, relapse, DSmurf, DHDAC1, Line, HOW, How, DHDAC3, DHDAC4, Inhibitors, Relapses, dRPD3, protein aggregate, dRpd3, drug resistance, Formal Social Controls, hdac1, l(3)j5D5, hdac3, Survival Times, hdac4, HDAC, 24B, xi-lactone, treatment, SET, me75, LCMSMS, TAF-I, Recurrences, stru, l(3)S053606, Hdac 3, CG10293, D17Mit170, T1, DmelCG4299, Social, l(3)j5B5, IGAAD, set, DmelCG10574, Smurf, disease management, Therapies, Deacetylase Inhibitors, s, Malignancies, L-Valine, CG4943, Tumors, D-smurf, LC-MS2, Therapy, phapii, Relapse, 0904/17, N-(3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(Z)-2, statistics and numerical data, CG7471, Mean Survival, LC-MS/MS, FR-901228, StF-IT-1, DRpd3, Lack, Tl3, Tl2, Girl, rpd[3], TPSG1, N1-Hydroxy-N8-phenyloctanediamide, S-adenosyl-L-methionine:thiol S-methyltransferase activity, M344, Benign, Recrudescence, SZ1, dmHDA405, dmHDA402, dmHDA401, BRCA, numerical data, N-Hydroxy-N'-phenyloctanediamide, GC1770, Su(var)3-26, HD7, HD9, N Hydroxy N' phenyloctanediamide, Lines, N1 Hydroxy N8 phenyloctanediamide, drpd3, HLA-DR-associated protein II, Time, DmelCG4943, DI-2, Suberoylanilide Hydroxamic Acid, I-2Dm, Control, Benign Neoplasms, CG4299, Controls, FR901228, E(var)3-64BC, Treatments, Malignant Neoplasms, Dromel_CG2128_FBtr0078767_hdac3_mORF, I-2PP1, TAF-IBETA, liquid chromatography-tandem mass spectroscopy, PRSS31, FK228, anon-EST:Liang-2.39, TAF-Ibeta, Inhibitor, i2pp2a, TMT, Regulation, HDAC-1, Regulations, DmelCG1770, Suberoyl Anilide Hydroxamic Acid, l(3)64Cc, RPD3, P62, Neoplasms, dSmurf1, dHDAC-1, drug susceptibility/resistance, Benign Neoplasm, Gene, istodax, protein-containing complex, Malignant, PHAPII, LC-MS-MS, Rate, HD7b, Survival Rate, utilization, Survival, Girls, LC-MSMS, Gene Products, HDAC7B, Low, rpd3, Zolinza, MITR, study, l(3)s2612, dHDAC4, Malignancy, dHDAC3, Recrudescences, ipp2a2, 2pp2a, dHDAC1, labeling, Deacetylase Inhibitor, CG10574, 3-didehydro-2-aminobutanoyl-, 18F-SAHA, (S-(E))-, l(3)04556, Mean Survival Times, Neoplasias, Cumulative, d-smurf, 2PP2A, taf-ibeta, DmelCG10293, dSET, dSet, malignant ovarian serous tumour, serous ovarian cancer, thiol methyltransferase activity, CG2128, HDAC9B, Cancer, MK0683, use, Malignant Neoplasm, cou, Women's Group, Survival Rates, Formal Social Control, Cumulative Survival Rate, Drug resistance, clone 2.39, protein complex, Women Groups, Proteins, igaad, Cell Lines, Suberanilohydroxamic Acid, Hdac1, qkr, Dsmurf, l(3)S090417, Woman, Histone, MK-0683, HDAC9FL, Histone Deacetylase Inhibitor, Cell, group, dSmurf, Mean Survival Time, Cumulative Survival Rates, LC/MS/MS, disease management., Lr, MT, native protein, I-2PP2A, Social Control, Su(var)326, Smurf ubiquitin ligase, KH93F, Dm I-2, Protein, I2PP2A, Neoplasm, Resistance, Su(var)328, Cumulative Survival, CG1770, who, DDA, Mean, Rates, Survival Time, HDAC3, HDAC1, DmelCG2128, ensemble, Histone Deacetylase, HDAC7, Women's Groups, response to drug, Cancers, Who/How, MK 0683, Rpd3/HDAC, Drug, Protein Gene Products, Gene Proteins, dSET/TAF-Ibeta, NHNPODA, 2610030F17Rik, Therapeutic, NIHOVCAR3, Bra, qkr[93F], liquid chromatography tandem mass spectrometry, DmHDAC3, HDAC4a, Treatment, regulation, DmHDAC1, Times, HDAC Inhibitors, AA407739, cyclic (1-2)-disulfide, General activity, NeoplasiaDeacetylase Inhibitors, Inhibitors, malignant ovarian serous tumour, serous ovarian cancer., HDAC Inhibitors, Inhibitor, HDAC Inhibitor, Deacetylase Inhibitor, Histone, Histone Deacetylase Inhibitor, Histone Deacetylase, HDACfalseDifferential histone deacetylase inhibitor-induced perturbations of the global proteomic landscape in the setting of high-grade serous ovarian cancerthis project carried out a global mass spectrometry analysis in a panel of HGSOC cell lines analyzing proteomic perturbations following HDACi treatment2022-11-042022-09-02PXD036467NEWT:6945NEWT:3555NEWT:2NEWT:157546NEWT:35554NEWT:38942NEWT:307972NEWT:32046NEWT:544496NEWT:2042546NEWT:45351NEWT:43179NEWT:4513NEWT:5722NEWT:376741NEWT:55153NCBITaxon:10407NEWT:1736309NEWT:309800NEWT:1211601NEWT:876138NEWT:557436NEWT:3654NEWT:237561NEWT:5833NEWT:6928NEWT:10036NEWT:36745NEWT:1351NEWT:1438992NEWT:2649997NEWT:272563NEWT:79220NEWT:224326NCBITaxon:79857NEWT:1096976NEWT:95648NEWT:3885NEWT:3888NEWT:1589NEWT:135622NCBITaxon:4896NEWT:6915NEWT:3649NEWT:101510NEWT:3880NEWT:272559NEWT:3641NEWT:383379NEWT:466585NEWT:10029NEWT:1000589NEWT:85963NEWT:85962NEWT:317447NEWT:7955NEWT:7959NEWT:2261NEWT:31156NEWT:398580NEWT:4565NEWT:1264690NEWT:515619NEWT:192875NEWT:34305NEWT:59729NCBITaxon:183674NEWT:224308NEWT:84645NEWT:626528NEWT:139927NEWT:4558NEWT:209285NEWT:5888NEWT:211586NEWT:1283NEWT:931281NEWT:4550NEWT:1000561NEWT:197NCBITaxon:79824NEWT:4787NCBITaxon:4563NEWT:5755NEWT:44689NEWT:3218NEWT:5759NEWT:1736231NEWT:1270NEWT:2242NEWT:4784NEWT:11320NEWT:360106NEWT:286NEWT:287NEWT:10117NEWT:10239NEWT:10116NEWT:1280NEWT:1735272NEWT:83334NEWT:83332NEWT:44685NEWT:317513NEWT:1148NEWT:580240NEWT:294128NEWT:11676NEWT:55571NEWT:100226NEWT:4530NEWT:4896NEWT:75058NEWT:13616NEWT:1390NEWT:1094343NEWT:296543NEWT:1773NEWT:1895NEWT:1182590NEWT:3712NEWT:935293NEWT:64152NEWT:4924NEWT:749200NEWT:990346NEWT:145953NEWT:257309NEWT:100816NEWT:263NEWT:230741NEWT:52283NEWT:284812NCBITaxon:1313NEWT:43330NEWT:980415NEWT:1603293NEWT:408169NEWT:44544NEWT:4911NEWT:645463NEWT:3702NEWT:129249NEWT:243277NEWT:990119NEWT:408172NEWT:408170NEWT:493760NEWT:260710NEWT:257313NEWT:400772NEWT:3708NEWT:128161NEWT:332648NEWT:106592NEWT:536231NEWT:460519NEWT:1187947NEWT:1432138NEWT:10312NEWT:1424507NCBITaxon:1773NEWT:9598NEWT:8030NEWT:1639NEWT:188229NEWT:3818NEWT:480NEWT:4909NEWT:67767NEWT:432359NEWT:46835NEWT:1182263NEWT:2711NEWT:376686NEWT:95486NEWT:9103NEWT:29159NEWT:253NEWT:10306NCBITaxon:2759NEWT:1233435NEWT:93061NEWT:8022NEWT:145943NCBITaxon:4932NEWT:595536NEWT:240906NEWT:593117NEWT:3635NEWT:5811NEWT:235443NEWT:272624NEWT:2719099NEWT:411483NEWT:884019NEWT:198215NEWT:411490NEWT:983964NEWT:169963NEWT:32644NEWT:225117NEWT:499175NEWT:109779NEWT:476272NEWT:3747NEWT:195051NEWT:367830NEWT:1255228NEWT:178616NEWT:410289NEWT:373153NEWT:352472NEWT:357NEWT:360094NEWT:470NEWT:1313NEWT:411469NEWT:84023NEWT:559292NEWT:39491NCBITaxon:5811NEWT:411464NEWT:411460NEWT:2014887NEWT:2762NEWT:1174673NEWT:562NEWT:411470NEWT:33952NEWT:2094720NCBITaxon:2697049NEWT:571256NEWT:28038NEWT:1663NEWT:1423NEWT:4932NEWT:3603NEWT:2759NEWT:3847NEWT:327159NEWT:178876NEWT:327160NEWT:573NEWT:9031NEWT:7091NEWT:241368NEWT:42528NEWT:190802NEWT:9778NEWT:150475NEWT:303NEWT:9417NEWT:7111NEWT:347515NEWT:1216979NEWT:5180NEWT:256737NEWT:115104NEWT:1121114NEWT:663NEWT:1081927NEWT:1238993NEWT:67825NEWT:185579NEWT:941442NEWT:220668NEWT:13076NEWT:1249668NEWT:7108NEWT:317NEWT:7227NEWT:7469NEWT:885318NEWT:9402NEWT:415540NEWT:550NEWT:675060NEWT:4081NEWT:334542NEWT:554NEWT:98334NEWT:426428NEWT:7574NEWT:1715256NEWT:7215NEWT:575412NEWT:29204NEWT:2172103NEWT:507601NEWT:643680NCBITaxon:6157NEWT:746360NEWT:6239NEWT:470150NEWT:216257NEWT:102169NEWT:9986NEWT:4054NEWT:73239NEWT:226186NEWT:1268063NEWT:8782NEWT:1263854NEWT:435590NEWT:1902NEWT:160488NEWT:28104NEWT:1908NCBITaxon:2NEWT:985076NEWT:1215323NEWT:623NEWT:52641NEWT:7038NEWT:6192NEWT:28532NCBITaxon:38727NEWT:198618NEWT:353152NEWT:2829NEWT:366581NEWT:216599NEWT:216595NEWT:51329NEWT:243230NEWT:8355NEWT:9685NEWT:7029NEWT:1080772NEWT:8479NEWT:1283300NEWT:6183NEWT:6063NEWT:334747NEWT:61235NEWT:6289NEWT:436486NEWT:6287NEWT:300641NEWT:727NEWT:9796NEWT:725NEWT:170187NEWT:260707NCBITaxon:6191NEWT:1836NEWT:185431NEWT:29760NEWT:260704NEWT:703612NEWT:260705NEWT:80863NEWT:2697049NEWT:105231NEWT:1216981NCBITaxon:6073NEWT:884204NEWT:6279NEWT:1123869NEWT:9544NEWT:7370NEWT:83906NEWT:607699NEWT:6282NEWT:426688NEWT:208964NEWT:1134506NEWT:575584NEWT:38783NEWT:8727NEWT:4006NEWT:8726NEWT:6426NEWT:6669NEWT:10090NEWT:4120NEWT:51515NEWT:5693NEWT:8724NEWT:51511NEWT:92867NEWT:8723NEWT:5334NEWT:37334NEWT:382352NCBITaxon:10359NEWT:242619NEWT:632957NEWT:34073NEWT:373995NEWT:5689NEWT:544404NEWT:9925NEWT:8839NEWT:4232NEWT:2758385NEWT:37349NEWT:4113NEWT:837NEWT:11298NEWT:171101NEWT:714NEWT:36015NEWT:421932NEWT:196627NEWT:5691NEWT:48479NEWT:627025NEWT:1097677NEWT:242507NEWT:61674NEWT:1117957NEWT:9913NEWT:8709NEWT:4100NEWT:1076NEWT:6763NEWT:3498NEWT:803NEWT:29722NEWT:380394NEWT:1692259NEWT:180066NEWT:135588NEWT:1843183NEWT:58002NEWT:326423NEWT:36111NEWT:4577NEWT:1416333NEWT:5664NEWT:2157NEWT:1678078NEWT:749906NEWT:418985NEWT:146479NEWT:1911079NEWT:69373NCBITaxon:620NEWT:264203NEWT:1480154NEWT:1274414NEWT:27606NEWT:59202NEWT:9975NEWT:9612NEWT:38865NEWT:51953NEWT:3197NEWT:9615NEWT:10299NEWT:860688NEWT:36329NEWT:1147787NCBITaxon:3044782NEWT:72407NEWT:1355477NEWT:349741NEWT:9605NEWT:9606NEWT:90371NEWT:157295NEWT:641501NEWT:7668NEWT:915099NEWT:74940NEWT:9721NEWT:137221NEWT:9600NEWT:1450511NEWT:1143193NEWT:411901NEWT:9838NEWT:105884NCBITaxon:9615NEWT:9839NEWT:58334NEWT:1193501NEWT:3055NEWT:58331NEWT:6326NEWT:6689NEWT:5476NEWT:299767NEWT:1274432NEWT:1274426NEWT:70448NEWT:9825NEWT:1274423NEWT:393765NEWT:698936NEWT:39946NEWT:9823NEWT:9940NEWT:95602NEWT:521001NEWT:39947NEWT:1274420NEWT:578458361937840000-0001-7711-5373